NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults

 NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults

NICE Publishes Final Recommendation for Almirall’s Ilumetri (tildrakizumab) to Treat Moderate-To-Severe Plaque Psoriasis in Adults

Shots:

  • NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission in Aug’18
  • Ilumetri (tildrakizumab) is evaluated in P-III reSURFACE 1 and 2 study in 1,800 patients > 200 sites across the globe resulted in maintaining PASI 75 in 9/10 patients @148wks. and >50% of patients reported no psoriasis after 3 doses, well tolerated with low SAEs & discontinuation rates
  • Ilumetri (tildrakizumab) is a humanized immunoglobulin mAb inhibits IL-23 by binding to its p19 subunit and has received approval from the European Commission on Sep’18 and provisional approval from NICE on Mar 8, 2019

Click here to read full press release/ article | Ref: Almirall | Image: Blickfang Messebau GmbH

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post